Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Non-Current Assets (2016 - 2025)

Editas Medicine (EDIT) has disclosed Non-Current Assets for 11 consecutive years, with $24.9 million as the latest value for Q3 2025.

  • On a quarterly basis, Non-Current Assets fell 55.94% to $24.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was $143.7 million, a 67.92% decrease, with the full-year FY2024 number at $52.3 million, down 66.98% from a year prior.
  • Non-Current Assets was $24.9 million for Q3 2025 at Editas Medicine, down from $27.8 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $170.2 million in Q4 2021 to a low of $24.9 million in Q3 2025.
  • A 5-year average of $110.2 million and a median of $126.1 million in 2022 define the central range for Non-Current Assets.
  • Peak YoY movement for Non-Current Assets: skyrocketed 255.45% in 2021, then tumbled 71.78% in 2025.
  • Editas Medicine's Non-Current Assets stood at $170.2 million in 2021, then fell by 7.41% to $157.6 million in 2022, then rose by 0.48% to $158.3 million in 2023, then plummeted by 66.98% to $52.3 million in 2024, then tumbled by 52.44% to $24.9 million in 2025.
  • Per Business Quant, the three most recent readings for EDIT's Non-Current Assets are $24.9 million (Q3 2025), $27.8 million (Q2 2025), and $38.8 million (Q1 2025).